Current Report Filing (8-k)
July 27 2022 - 4:34PM
Edgar (US Regulatory)
0000744452
false
0000744452
2022-07-27
2022-07-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
July 27, 2022
Applied DNA Sciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation) |
001-36745
(Commission File Number) |
59-2262718
(IRS Employer
Identification No.) |
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of principal executive offices; zip code)
Registrant’s telephone number, including
area code:
631-240-8800
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value |
|
APDN |
|
The
Nasdaq Stock Market
|
Item 7.01 Regulation FD Disclosure.
On July 27, 2022, Applied DNA Sciences, Inc. (the
“Company”), made a technology and data presentation at the 2nd Annual mRNA-Based Therapeutics Summit in Boston, Massachusetts.
The presentation is available on the Company’s website at www.adnas.com and may also be used in presentations to investors and analysts
from time to time in the future. A copy of the Company’s presentation is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
The information contained in this Current Report
on Form 8-K speaks only as of the date hereof. While the Company may elect to update the information in this Current Report
on Form 8-K in the future, the Company disclaims any obligation to do so except to the extent required by applicable law.
The information furnished
in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K is not incorporated
by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless
specifically stated so therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: July 27, 2022 |
APPLIED DNA SCIENCES, INC. |
|
|
|
|
|
|
By: |
/s/ James A. Hayward |
|
|
Name: |
James A. Hayward |
|
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024